Itralent 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections, including aspergillosis, histoplasmosis, blastomycosis, onychomycosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. The capsule formulation ensures optimal bioavailability when taken with food. Itralent 200 is typically administered orally, with dosage and duration tailored according to the severity and type of infection, as well as patient response. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals and should be used cautiously in individuals with hepatic impairment or congestive heart failure. Potential adverse effects include gastrointestinal disturbances, headache, rash, and hepatotoxicity; regular monitoring of liver function tests is recommended during prolonged therapy. Itralent 200 may interact with several drugs metabolized by the cytochrome P450 system, necessitating careful review of concomitant medications. This medication should be prescribed and used under the supervision of a qualified healthcare professional to ensure safety and efficacy.